Herbal extract may ease the toll of lung cancer immunotherapy

NCT ID NCT04348149

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This pilot study tests whether a daily herbal supplement made from Lindera obtusiloba can improve quality of life for people with non-small cell lung cancer who are receiving PD-1 or PD-L1 inhibitor immunotherapy. About 20 adults will take the supplement for 8 weeks alongside their usual treatment. Researchers will measure changes in quality of life, lung cancer symptoms, and immune cell levels to see if the supplement offers any benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lindera obtusiloba extract (a herbal dietary supplement)
What this could lead to
If effective, this herbal supplement could offer a natural way to improve quality of life and reduce symptoms for lung cancer patients undergoing immunotherapy.
What could go wrong
This is a small pilot study with only 20 participants, so results may not be conclusive. The supplement's safety and effectiveness are not yet established, and it may not provide significant benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Korean Medicine Hospital, Pusan National University

    Yangsan, Gyeongsangnam-do, 50612, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.